I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
1 Department of Pediatrics, Dokkyo Medical University School of Medicine, 880 Kita-Kobayashi, Mibu, Tochigi, Japan, 321-0293
2 Department of Nuclear Medicine, Kanazawa University, Kanazawa, Ishikawa, Japan
Italian Journal of Pediatrics 2012, 38:53 doi:10.1186/1824-7288-38-53Published: 15 October 2012
Iodine-131-metaiodiobenzylguanidine (131I-MIBG) therapy combined with allogeneic cord blood stem cell transplantation (SCT) was used to treat a 4-year-old girl with recurrent neuroblastoma. The patient experienced relapse 2 years after receiving first-line therapies, which included chemotherapy, surgical resection, irradiation, and autologous peripheral SCT. Although 131I-MIBG treatment did not achieve complete remission, the size of the tumor was reduced after treatment. Based on our findings, we suggest that 131I-MIBG treatment with myeloablative allogeneic SCT should be considered as first-line therapy for high-risk neuroblastoma patients when possible.